R
About
Relation Therapeutics is a London-based biotechnology company founded in 2020, operating at the intersection of deep biology and artificial intelligence to develop transformational medicines. At the core of their approach is the Lab-in-the-Loop platform — a tightly integrated system that combines single-cell multi-omics directly from patient tissue, high-throughput functional assays, and cutting-edge machine learning models to decode the root causes of complex diseases. The company's ambition is to understand human biology in unprecedented detail, moving from disease cause to therapeutic cure with speed and precision not achievable through traditional drug discovery methods. Relation leverages NVIDIA's CAMBRIDGE-1 supercomputer and collaborates with Nobel laureates, academic institutions such as Mila, Scripps Research, and industry leaders including Yoshua Bengio to push the frontier of digital biology. With a $60M seed round co-led by DCVC and NVIDIA's N Ventures, strategic partnerships with GSK (including a $15M equity investment) and Novartis, and a collaboration with Deerfield Management, Relation is rapidly advancing a pipeline of novel therapeutics. Their first disclosed indication is osteoporosis, with additional programs in atopic diseases. Relation is designed for scientists, drug developers, and computational researchers seeking to redefine how medicines are discovered and developed.
Key Features
- Lab-in-the-Loop Platform: A seamlessly integrated system combining single-cell analysis, genomics, and machine learning to accelerate target identification and drug development.
- Single-Cell Multi-Omics: Direct profiling of patient tissue at single-cell resolution to uncover disease biology with unprecedented granularity.
- AI-Driven Target Discovery: Machine learning models trained on high-resolution biological data to identify and validate druggable targets for complex diseases.
- High-Performance Computing: Access to NVIDIA's CAMBRIDGE-1 supercomputer, the UK's most powerful, enabling large-scale digital biology computations.
- Strategic Industry Partnerships: Collaborations with GSK, Novartis, and Deerfield Management to co-develop and advance novel therapeutics to the clinic.
Use Cases
- Identifying novel drug targets for complex diseases using patient-derived single-cell multi-omics data
- Accelerating preclinical drug discovery by integrating AI with high-throughput functional assays
- Forming strategic co-development partnerships with major pharmaceutical companies to advance therapeutic programs
- Applying large-scale machine learning on supercomputing infrastructure to model disease mechanisms
- Developing precision medicines for high-unmet-need diseases such as osteoporosis and atopic conditions
Pros
- End-to-End Integration: Combines experimental biology, genomics, and AI in a single closed-loop platform, reducing bottlenecks across the drug discovery pipeline.
- World-Class Collaborators: Partnerships with Nobel laureates, top academic institutions, and major pharma companies validate the scientific and commercial approach.
- Patient-Centric Focus: Uses direct patient tissue data to ground discoveries in real-world disease biology rather than model systems alone.
Cons
- Not a Consumer-Facing Tool: Relation Therapeutics is a private biotech company, not a software product accessible to individual researchers or developers.
- Early Pipeline Stage: As of 2024-2026, the company's drug programs are still in early development, with no approved therapies on the market yet.
Frequently Asked Questions
What is Relation Therapeutics?
Relation Therapeutics is an AI-driven, end-to-end biotechnology company that uses single-cell multi-omics, functional assays, and machine learning to identify drug targets and develop transformational medicines for devastating diseases.
What is the Lab-in-the-Loop platform?
Lab-in-the-Loop is Relation's proprietary technology platform that integrates single-cell analysis, genomics, and machine learning in a closed-loop cycle, enabling rapid iteration between wet lab experiments and computational analysis to accelerate drug discovery.
What diseases is Relation Therapeutics focused on?
Relation's first disclosed indication is osteoporosis. The company also has programs in atopic diseases through a strategic collaboration with Novartis, and is advancing additional targets through its partnership with Deerfield Management.
Who has invested in or partnered with Relation Therapeutics?
Relation has raised a $60M seed round co-led by DCVC and NVIDIA's N Ventures, secured a $15M equity investment from GSK, and entered strategic collaborations with Novartis and Deerfield Management. Academic partners include Mila, Scripps Research, and Yoshua Bengio.
Where is Relation Therapeutics headquartered?
Relation Therapeutics is headquartered at Regent's Place, 338 Euston Road, London, NW1 3BG, United Kingdom. The company was founded in January 2020.
